No difference in efficacy between generic antiepileptic drugs
Switching between generic antiepileptic drugs does not lead to significant changes in seizure frequency or adverse events, study finds.
Switching from branded to generic antiepileptic drug (AED) products can significantly lower the costs of treatment. However, there has been widespread scepticism about the bioequivalence of generic products and the safety of generic-to-generic switching.
US researchers report in The Lancet Neurology (online, 11 February 2016) on a randomised study in which 35 patients alternated between the two most different generic lamotrigine products for four cycles of 14 days.
They found that pharmacokinetic measures of the drugs were equivalent and there were no significant changes in seizure frequency or adverse events between the two.
The team says the findings could prompt pharmaceutical bodies to reassess their opinions on generic substitution. At present in the UK, the Medicines and Healthcare products Regulatory Agency divides AEDs into three risk categories to help prescribers decide on product selection for patients.
Citation: Clinical Pharmacist DOI: 10.1211/CP.2016.20200723
Recommended from Pharmaceutical Press
This new edition of Dale and Appelbe's Pharmacy and Medicines Law is the definitive guide to law and ethics for pharmacy practice in the UK. It covers law and professional regulation and is firmly established as the definitive student textbook and reference work on this subject in the UK. Fully updated to include changes to pharmacy laws and regulation.£57.00Buy now